Acquired Company

Day One Biopharmaceuticals, Inc. acquired Mersana Therapeutics, Inc. on 1/6/2026 for $25 per share in cash, plus one non-tradable contingent value right (CVR) per share.

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to developing targeted therapies for genetically defined cancers. The company is advancing an innovative pipeline designed to meet critical unmet medical needs in oncology, utilizing precision medicine approaches to improve treatment outcomes by targeting specific genetic mutations. With a strong commitment to transforming cancer therapeutics, Day One seeks to make a substantial impact on the biopharmaceutical sector and enhance the quality of life for patients battling these complex diseases. Show more

Location: 1800 SIERRA POINT PARKWAY, BRISBANE, CA, UNITED STATES, 94005, Suite 217, Brisbane, CA, 94005, USA | Website: https://dayonebio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.146B

52 Wk Range

$5.63 - $13.20

Previous Close

$11.16

Open

$11.18

Volume

1,555,872

Day Range

$11.02 - $11.53

Enterprise Value

697.2M

Cash

43.28M

Avg Qtr Burn

-5.805M

Insider Ownership

16.94%

Institutional Own.

85.98%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emi-Le/Emiltatug Ledadotin (Emi-Le) (B7-H4 ADC) Details Cancer, Adenoid Cystic Carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DAY301 (formerly MTX-13) Details Solid tumor/s	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.